Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients...
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of...
As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 24 janvier 2025 – Inventiva (Euronext Paris...
Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA...
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 Daix (France), New York City (New York...
Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025 Daix (France), New York City (New...
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company...
Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.05 | -2.26244343891 | 2.21 | 2.705 | 2.155 | 68972 | 2.40749617 | DE |
4 | -0.03 | -1.3698630137 | 2.19 | 2.705 | 2.08 | 26363 | 2.32376859 | DE |
12 | -0.28 | -11.4754098361 | 2.44 | 2.705 | 2 | 22254 | 2.3517573 | DE |
26 | -0.03 | -1.3698630137 | 2.19 | 3.2 | 1.434 | 37891 | 2.28468515 | DE |
52 | -1.42 | -39.6648044693 | 3.58 | 4.3 | 1.434 | 45383 | 2.79298946 | DE |
156 | -8.54 | -79.8130841121 | 10.7 | 12 | 1.434 | 53779 | 3.72284405 | DE |
260 | -1.94 | -47.3170731707 | 4.1 | 16.3 | 1.434 | 62732 | 7.11338164 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관